Botwood Nicholas A.J. 4

What Happened

• Nicholas A.J. Botwood, Syndax’s Head of R&D and Chief Medical Officer, exercised stock options and sold shares in transactions reported for June 11–12, 2026. He exercised a total of 53,750 shares at an exercise price of $13.82 (total cash paid reported $742,825) and sold 65,515 shares in open‑market transactions for total proceeds of approximately $1,183,643.
• The June 11 sale (34,280 shares) had a weighted‑average price of $18.00 (range $17.31–$18.10). The June 12 sale (31,235 shares) had a weighted‑average price of $18.14 (range $18.00–$18.32). On June 12 the exercised shares and sales match in quantity (31,235), indicating those exercised shares were sold the same day.

Key Details

• Transaction dates: June 11, 2026 and June 12, 2026.
• Exercises: 22,515 shares (6/11) and 31,235 shares (6/12) at $13.82 each (cash reported $311,157 and $431,668).
• Sales: 34,280 shares (6/11) at weighted avg $18.00 (proceeds $617,040); 31,235 shares (6/12) at weighted avg $18.14 (proceeds $566,603). Total sale proceeds ≈ $1,183,643.
• Options remaining (per filing): 16,537 options vested & immediately exercisable; 289,413 options not yet vested.
• Footnotes: Sales were made pursuant to a Rule 10b5‑1 trading plan. Prices reported are weighted averages across multiple trades (ranges provided). The filing notes the shares sold were fully vested.
• Timeliness: Form 4 was filed on June 12, 2026 for transactions on June 11–12 — within the typical two‑business‑day reporting window.

Context

• This was an options exercise followed by open‑market sales. The same‑day exercise and sale on June 12 is effectively a cashless disposition of those exercised shares. The June 11 sale exceeded that day’s exercises, indicating some sold shares likely came from existing holdings. These transactions were executed under a prearranged 10b5‑1 plan, which is common for routine insider sales and does not, by itself, imply judgment about future company prospects.